Search Results

1 - 7 of 7 items :

  • pharmacokinetics x
  • Pharmacology x
  • Clinical Medicine x
Clear All
How specialist nurse-led care can help to lower the costs of prophylaxis

References 1 Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematology 2010; 149: 498;507. 2 Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 <Suppl 1=: 94;9.. 3 Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical

Open access
Into the future with novel emerging therapies for haemophilia

VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123(3): 317-25. doi: 10.1182/blood-2013-10-529974. 9. Collins PW, Fischer K, Morfini M, et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2-10. 10. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13(5): 743-54. doi: 10

Open access
Successful immune tolerance in two children with severe haemophilia A

: 3858B3864. 4. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1997; 55: 638B648. 5. Yatuv R, Dayan I, CarmelBGoren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 2008; 14: 476B483 6. Weimer T, Wormsbächer W, Kronthaler U, et al. Prolonged inBvivo half life of factor VIIa by fusion to albumin. Thromb Haemost 2008; 99: 659B667 7. Leissinger C, Gringeri A, Antmen B

Open access
The use of tranexamic acid in reducing bleeding complications

References 1. Nilsson IM. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980;14:41-7. 2. Wikipedia. Tranexamic acid. Available from: (accessed 18 March 2016). 3. Grassin-Delyle S, Tremey B, Abe E, et al. Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth 2013;111:916-24. 4. Pfizer Ltd. Cyclokapron injection. 5.1 Pharmacodynamic

Open access
Guidelines for the management of haemophilia in Egypt

-8. 25. Fischer K, van der Bom JG, Molho P, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745-52. 26. Elekiaby A, El Saied H, Elekiaby M. Five years of tailored low dose prophylaxis in a small cohort of kids with severe hemophilia A using SD-F cryoprecipitate. Poster no. PO169 presented at the World Federation of Hemophilia Congress; 24-28 July 2016; Orlando, FL. 27. El-Kiaby M, Goubran HA, Radosevich M, et al. Pharmacokinetic study of

Open access
Safety of concomitant treatment with Non-Vitamin K Oral Anticoagulants and SSRI/SNRI antidepressants

, Mancuso A, Andò G, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018; 14:1057-1069. 5. Dexxience [EU]. BevyxXa [US] · Venous thromboemolism (VTE) prevention - first line - in at risk adult patients hospitalised for an acute medical illness [Cited 13.01.2019]. Accessible at: 6. Gelosa P, Castiglioni L, Tenconi M, Baldessin L, Racagni G, Corsini A, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants

Open access
Adriamycin - efficacy and possible adverse effects

): 270-281. 8. Wcisło G., Korniluk J., Szarlej-Wcisło K., Pawlak W.Z., Nurzyński P., Duchnowska R.: Leczenie chorób nowotworowych czynnikiem martwicy nowotworów – alfa (TNF-alfa). Współczesna Onkologia, 2002; 4: 222–227. 9. Gabizon et al . Pharmacokinetics of Pegylated Liposomal Doxorubicin Review of Animal and Human Studies. Clin Pharmacokinet 2003; 42 (5): 419-436. 10. National Institute for Health and Clinical Excellence; TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydro-chloride and topotecan (review): Guidance

Open access